基本信息

张翾 男 硕导 中国科学院上海药物研究所
电子邮件: zhangxuan@simm.ac.cn
通信地址: 上海市松涛路647弄2幢2-226
邮政编码: 201203
电子邮件: zhangxuan@simm.ac.cn
通信地址: 上海市松涛路647弄2幢2-226
邮政编码: 201203
招生信息
招生专业
100701-药物化学
招生方向
蛋白降级剂的设计与生物学研究
教育背景
2009-09--2014-05 华东师范大学 博士学位2001-09--2005-06 上海师范大学 学士学位
工作经历
工作简历
2019-07~2020-12,美国佛罗里达大学, 科研助理教授2018-06~2019-07,美国佛罗里达大学, 博士后2014-12~2018-05,美国阿肯色大学医学部, 博士后2014-08~2014-11,华东师范大学, 科研助理2005-07~2009-09,中国科学院上海药物研究所, 研究助理
专利与奖励
专利成果
( 1 ) Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof, 发明, 2016, 第 3 作者, 专利号: PCT/US2017/028875
出版信息
发表论文
(1) A Concise Synthesis of (S)-δ-CEHC, a Metabolite of Vitamin E, ACS Omega, 2021, 通讯作者(2) Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells, Nat. Commun., 2021, 其他(合作组作者)(3) Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs, Chem. Commun., 2020, 通讯作者(4) Using proteolysis targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity, Nat. Commun., 2020, 第 2 作者(5) Discovery of IAP-Recruiting BCL-XL PROTACs as Potent Degraders across Multiple Cancer Cell Lines, Eur. J. Med. Chem., 2020, 第 1 作者(6) Discovery of PROTAC BCL-XL Degraders as Potent Anticancer Agents with Low On-target Platelet Toxicity, Eur. J. Med. Chem., 2020, 第 1 作者(7) Targeting anti-apoptotic BCL-2 family proteins for cancer treatment, Future Med. Chem., 2020, 第 1 作者(8) Recent advances in small molecular modulators targeting histone deacetylase 6, Future Drug Discov., 2020, 通讯作者(9) PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors, Explor. Targeted Antitumor Ther., 2020, 第 2 作者(10) Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies, J. Hematol. Oncol., 2020, 第 5 作者(11) DT2216 – a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T-cell lymphomas, J. Hematol. Oncol., 2020, 第 5 作者(12) PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics, Oncogene, 2020, 第 3 作者(13) Assays and Technologies for Developing Proteolysis Targeting Chimera Degraders, Future Med. Chem., 2020, 第 2 作者(14) Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity, Aging Cell, 2020, 第 5 作者(15) Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorine‐Substituted δ‐Tocotrienol Derivative, ChemMedChem, 2020, 第 5 作者(16) Deuteration of the farnesyl terminal methyl groups of δ-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production, Bioorg. Med. Chem., 2020, 第 6 作者(17) Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL. Chem. Commun, Chem. Commun., 2019, 第 1 作者(18) A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity, Nat. Med., 2019, 第 2 作者
科研活动
参与会议
(1)Discovery of BCL-XL degraders as potent and platelet-sparing anticancer agents 2019-08-26(2)Induced Degradation of Bcl-xL: A PROTAC Approach to Target the Achilles’ Heel of Senescent Cells 2017-09-26